ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Genentech And Array Join ChK-1 Programs

by Lisa M. Jarvis
August 15, 2011 | APPEARED IN VOLUME 89, ISSUE 33

Genentech will pay Array BioPharma $28 million as part of a deal to jointly develop the companies’ small-molecule inhibitors of Checkpoint kinase 1 (ChK-1), a protein implicated in cancer cell survival. Included in the pact are Genentech’s GDC-0425, in Phase I studies, and Array’s ARRY-575, which has yet to be tested in humans. Array could gain up to $685 million in milestone payments along with royalties on any drug that is commercialized under the pact from either firm. ChK-1 helps a tumor cell to repair damaged DNA after exposure to chemotherapy; if the protein is blocked, chemotherapy should kill cancer cells more effectively.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment